JP2022507020A5 - - Google Patents
Info
- Publication number
- JP2022507020A5 JP2022507020A5 JP2021523948A JP2021523948A JP2022507020A5 JP 2022507020 A5 JP2022507020 A5 JP 2022507020A5 JP 2021523948 A JP2021523948 A JP 2021523948A JP 2021523948 A JP2021523948 A JP 2021523948A JP 2022507020 A5 JP2022507020 A5 JP 2022507020A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758364P | 2018-11-09 | 2018-11-09 | |
| US62/758,364 | 2018-11-09 | ||
| US201962916739P | 2019-10-17 | 2019-10-17 | |
| US62/916,739 | 2019-10-17 | ||
| PCT/US2019/060350 WO2020097389A1 (en) | 2018-11-09 | 2019-11-07 | Bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507020A JP2022507020A (ja) | 2022-01-18 |
| JP2022507020A5 true JP2022507020A5 (https=) | 2022-11-07 |
| JP7482861B2 JP7482861B2 (ja) | 2024-05-14 |
Family
ID=70611193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523948A Active JP7482861B2 (ja) | 2018-11-09 | 2019-11-07 | 二環式化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11866431B2 (https=) |
| EP (1) | EP3877356A4 (https=) |
| JP (1) | JP7482861B2 (https=) |
| KR (1) | KR20210108367A (https=) |
| CN (1) | CN113302175A (https=) |
| AU (1) | AU2019375983A1 (https=) |
| BR (1) | BR112021008741A2 (https=) |
| CA (1) | CA3118752A1 (https=) |
| IL (1) | IL282984A (https=) |
| MX (1) | MX2021005314A (https=) |
| WO (1) | WO2020097389A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210108367A (ko) | 2018-11-09 | 2021-09-02 | 비바체 테라퓨틱스, 인크. | 비시클릭 화합물 |
| EP3917911A1 (en) * | 2019-01-31 | 2021-12-08 | Kyorin Pharmaceutical Co., Ltd. | 15-pgdh inhibitors |
| MX2021012638A (es) | 2019-04-16 | 2022-01-04 | Vivace Therapeutics Inc | Compuestos biciclicos. |
| JP2023524863A (ja) * | 2020-05-08 | 2023-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式のヘテロ環 |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| IL301691A (en) | 2020-09-30 | 2023-05-01 | Univ Leuven Kath | 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| CA3205726A1 (en) | 2021-01-25 | 2022-07-28 | Alfredo C. Castro | Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer |
| WO2022233442A1 (en) * | 2021-02-10 | 2022-11-10 | Merck Patent Gmbh | 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer |
| TW202304865A (zh) * | 2021-03-23 | 2023-02-01 | 美商百愛及生物醫藥公司 | Nlrp3發炎體之抑制劑 |
| WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| JP7843780B2 (ja) * | 2021-05-05 | 2026-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置に使用するための２，８－ジヒドロピラゾロ［３，４－ｂ］インドール誘導体 |
| CA3177022A1 (en) * | 2021-05-11 | 2022-11-11 | Opna Immuno-Oncology Sa | Compounds and methods for yap/tead modulation and indications therefor |
| WO2022240966A1 (en) | 2021-05-11 | 2022-11-17 | Opna Immuno-Oncology Sa | Compounds and methods for yap/tead modulation and indications therefor |
| JP2024519845A (ja) * | 2021-05-19 | 2024-05-21 | ジェネンテック， インコーポレイテッド | 併用療法 |
| TW202317104A (zh) * | 2021-06-25 | 2023-05-01 | 美商賽迪拉治療股份有限公司 | Ｔｅａｄ抑制劑及其用途 |
| KR20240046891A (ko) * | 2021-08-12 | 2024-04-11 | 티와이케이 메디슨즈, 인코포레이티드 | 다환 화합물 및 그의 용도 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN113861061A (zh) * | 2021-10-25 | 2021-12-31 | 成都市科隆化学品有限公司 | 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法 |
| CN114181039A (zh) * | 2021-12-23 | 2022-03-15 | 凯美克(上海)医药科技有限公司 | 一种4,4-二苯基-3-丁烯-1-醇的合成方法 |
| EP4452253A4 (en) | 2021-12-23 | 2026-04-15 | The Katholieke Univ Leuven | 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD |
| CN119053602A (zh) | 2022-01-28 | 2024-11-29 | 柏奥艾奇实验室公司 | Nlrp3炎性体的n-氧化物抑制剂 |
| AU2023225036A1 (en) * | 2022-02-25 | 2024-07-11 | Katholieke Universiteit Leuven | Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead |
| CN114539080A (zh) * | 2022-03-02 | 2022-05-27 | 八叶草健康产业研究院(厦门)有限公司 | 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法 |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| KR20250029773A (ko) * | 2022-03-22 | 2025-03-05 | 스포로스 바이오디스커버리, 인크. | Tead 억제제 및 사용 방법 |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| KR20250034120A (ko) * | 2022-07-06 | 2025-03-10 | 비비디온 테라퓨틱스, 인코포레이티드 | Wrn 헬리케이스 억제제를 포함하는 약제학적 조성물 |
| CN119968359A (zh) | 2022-09-29 | 2025-05-09 | 英矽智能科技知识产权有限公司 | Tead抑制剂及其使用方法 |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| US20240197715A1 (en) | 2022-11-18 | 2024-06-20 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| EP4669319A1 (en) | 2023-02-23 | 2025-12-31 | Novartis AG | TEAD AND HER2 INHIBITOR COMBINATIONS FOR CANCER TREATMENT |
| WO2024176131A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and kras g12d-inhibitor combinations for treating cancer |
| KR20260029501A (ko) * | 2023-05-24 | 2026-03-04 | 베액티카 테라퓨틱스 아베 | Tead에 대한 결합제로서의 방향족 아미드 및 이의 접합체 |
| WO2025054190A1 (en) * | 2023-09-05 | 2025-03-13 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a yap/taz-tead inhibitor |
| CN117327007B (zh) * | 2023-09-26 | 2024-09-13 | 上海陶术生物科技有限公司 | 一种vt107的制备方法 |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025141118A1 (en) | 2023-12-27 | 2025-07-03 | Institut National de la Santé et de la Recherche Médicale | Arylalkyloxyindole compounds and derivatives and their use |
| US12509459B2 (en) | 2024-03-26 | 2025-12-30 | BioAge Labs, Inc. | Inhibitors of NLRP3 inflammasome |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| AU6279598A (en) | 1997-02-18 | 1998-09-08 | Neurocrine Biosciences, Inc. | Biazacyclic CRF antagonists |
| PL341364A1 (en) | 1997-12-22 | 2001-04-09 | Upjohn Co | 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents |
| IT1303123B1 (it) * | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| US7067532B2 (en) | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
| FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| WO2006080477A1 (en) | 2005-01-25 | 2006-08-03 | Tanabe Seiyaku Co., Ltd. | Norvaline derivative and method for preparation thereof |
| BRPI0707302B8 (pt) | 2006-01-27 | 2021-05-25 | Fibrogen Inc | compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende |
| WO2007097929A1 (en) | 2006-02-16 | 2007-08-30 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| WO2008023157A1 (en) | 2006-08-21 | 2008-02-28 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as m3-receptor modulators |
| AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| CN101679357A (zh) * | 2007-05-09 | 2010-03-24 | 辉瑞大药厂 | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 |
| US20100254942A1 (en) * | 2007-08-03 | 2010-10-07 | Biotron Limited | Hepatitis c antiviral compositions and methods |
| EA019869B1 (ru) | 2007-11-28 | 2014-06-30 | Дана Фарбер Кансер Инститьют, Инк. | Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения |
| WO2009075826A1 (en) | 2007-12-07 | 2009-06-18 | Fibrogen, Inc. | Methods for increasing white blood cells |
| KR20120006016A (ko) * | 2009-04-06 | 2012-01-17 | 다이이찌 산쿄 가부시키가이샤 | 치환 페닐기를 갖는 고리형 화합물 |
| JP2012524800A (ja) * | 2009-04-22 | 2012-10-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド |
| EP2588455B1 (en) * | 2010-07-02 | 2018-04-04 | Gilead Sciences, Inc. | 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds |
| BR112013009828A2 (pt) | 2010-10-22 | 2016-07-26 | Janssen Pharmaceutica Nv | diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase |
| CA2743391A1 (en) * | 2011-05-27 | 2012-11-27 | Queen's University At Kingston | Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters |
| IN2014CN03234A (https=) * | 2011-11-03 | 2015-07-03 | Merck Sharp & Dohme | |
| US9012443B2 (en) | 2011-12-07 | 2015-04-21 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| EP2858635A1 (en) | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| EP3219706A1 (en) | 2012-07-16 | 2017-09-20 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| CN105163727B (zh) * | 2013-05-03 | 2018-08-17 | 豪夫迈·罗氏有限公司 | 刺激神经发生的异喹啉衍生物 |
| US20140336182A1 (en) | 2013-05-13 | 2014-11-13 | Amgen Inc. | Aurora Kinase Modulators and Method of Use |
| US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| US9452986B2 (en) | 2014-02-06 | 2016-09-27 | Abbvie Inc. | 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use |
| SG11201607973XA (en) | 2014-03-24 | 2016-11-29 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
| EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
| WO2018028591A1 (zh) | 2016-08-09 | 2018-02-15 | 殷建明 | 一种喹啉衍生物及其用途 |
| US11629220B2 (en) | 2017-08-21 | 2023-04-18 | Drexel Unversity | Renewable furan based amine curing agents for epoxy thermoset |
| CN117402114A (zh) | 2018-01-26 | 2024-01-16 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| EP3746135A4 (en) | 2018-01-30 | 2022-03-09 | Foghorn Therapeutics Inc. | METHODS AND COMPOUNDS FOR TREATMENT OF DISEASE |
| KR20210108367A (ko) | 2018-11-09 | 2021-09-02 | 비바체 테라퓨틱스, 인크. | 비시클릭 화합물 |
| MX2021012638A (es) | 2019-04-16 | 2022-01-04 | Vivace Therapeutics Inc | Compuestos biciclicos. |
| WO2022087008A1 (en) | 2020-10-21 | 2022-04-28 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
-
2019
- 2019-11-07 KR KR1020217017366A patent/KR20210108367A/ko not_active Ceased
- 2019-11-07 AU AU2019375983A patent/AU2019375983A1/en not_active Abandoned
- 2019-11-07 CN CN201980088541.5A patent/CN113302175A/zh active Pending
- 2019-11-07 CA CA3118752A patent/CA3118752A1/en active Pending
- 2019-11-07 US US17/291,765 patent/US11866431B2/en active Active
- 2019-11-07 EP EP19882564.8A patent/EP3877356A4/en not_active Withdrawn
- 2019-11-07 MX MX2021005314A patent/MX2021005314A/es unknown
- 2019-11-07 JP JP2021523948A patent/JP7482861B2/ja active Active
- 2019-11-07 WO PCT/US2019/060350 patent/WO2020097389A1/en not_active Ceased
- 2019-11-07 BR BR112021008741-9A patent/BR112021008741A2/pt not_active Application Discontinuation
-
2021
- 2021-05-06 IL IL282984A patent/IL282984A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022507020A5 (https=) | ||
| JP2020533280A5 (https=) | ||
| ES2791315T3 (es) | Agonistas triazoles del receptor APJ | |
| JP2018515581A5 (https=) | ||
| CA2970628C (en) | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors | |
| JP2022529642A5 (https=) | ||
| JP2022529700A5 (https=) | ||
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| ES2908938T3 (es) | Nuevos derivados de benzamida como moduladores de PPAR-gamma | |
| AU2009300318A1 (en) | Compounds for inflammation and immune-related uses | |
| TW202128644A (zh) | 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途 | |
| JP2019514883A5 (https=) | ||
| AU2002238855B2 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
| CA2885969A1 (en) | Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases | |
| AU2004268621A1 (en) | c-Kit modulators and methods of use | |
| PT1089998E (pt) | Derivados de epotilona e sua síntese e utilização | |
| EA026892B1 (ru) | ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1 | |
| JP2008520742A5 (https=) | ||
| JP2005505595A5 (https=) | ||
| JP2021523168A5 (https=) | ||
| ES2300775T3 (es) | Furazanobencimidazoles. | |
| ES2338060T3 (es) | Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer. | |
| EP3303290A1 (en) | Ror gamma (rory) modulators | |
| JP2018515491A5 (https=) | ||
| CN113056265A (zh) | 法尼醇x受体激动剂及其用途 |